# Economics.qmd Peer Review Improvement Plan

**Document**: `knowledge/economics/economics.qmd`
**Goal**: Prepare for academic peer review submission
**Status**: ‚ö†Ô∏è **~90% PEER-REVIEW READY** - Core structure complete, remaining economist critique responses in progress

---

## üìä CURRENT STATUS

**Core Academic Structure**: ‚úÖ **COMPLETE**
- Abstract, Methodology, Limitations, Hypothesis, Nomenclature, References all added
- Mathematical rigor verified, all calculations use parameters.py
- 435 parameters documented with confidence indicators

**Economist Critique Responses**: ‚úÖ **HIGH PRIORITY COMPLETE** - All critical items done
- ‚úÖ Expected value analysis (lines 627-656), general equilibrium (lines 1241-1262), peace dividend confidence levels (lines 445-449), discount rate sensitivity (lines 528-549)
- ‚úÖ Partnership model (line 754), platform costs distinction (line 826), cost comparison table, observational trial images (lines 1109-1115)
- ‚úÖ Pre-1962 context (lines 542-554), RECOVERY limitations (lines 1051-1062), time inconsistency (lines 607-626), counterfactual baseline (lines 413-429), regulatory risks (lines 1393-1477)
- ‚úÖ QALY confidence levels (lines 1258, 1262, 1266), external validity (lines 1352-1369), comparison rationale (lines 1045-1067)
- ‚úÖ Opportunity cost analysis (line 950), adoption realism (lines 571-580)
- ‚úÖ Monte Carlo simulation implemented with confidence intervals (line 526)
- ‚è≥ **Remaining (Medium Priority)**: Publication bias note, variable verification

---

## PENDING TODOS

### High Priority

#### 15. ‚úÖ Add Opportunity Cost Analysis - COMPLETED
**Location**: "Problem Statement and Opportunity Cost" section (line 946)
**Status**: COMPLETED - Added concise opportunity cost framework comparing to alternative uses (military R&D spillovers, tax cuts, other public investments) with note on dominant intervention status

#### 16. ‚úÖ Improve QALY Methodology with Confidence Levels - COMPLETED
**Location**: "QALY Calculation Uncertainties" section (lines 1258, 1262, 1266)
**Status**: COMPLETED - Confidence levels already documented (Stream A: High, Stream B: Medium, Stream C: Lower)

#### 17. ‚úÖ Enhance External Validity Discussion - COMPLETED
**Location**: "External Validity Considerations" section (lines 1352-1369)
**Status**: COMPLETED - Section exists with transferability across contexts, temporal validity, and general equilibrium effects

#### 18. ‚úÖ Add Adoption Realism Discussion - COMPLETED
**Location**: "Adoption Rate Assumptions" section (lines 571-580)
**Status**: COMPLETED - Added concise discussion of S-curve adoption, coordination failure risk with economic mitigation, and regulatory harmonization timeline (10-20 years)

### Medium Priority

#### 26. ‚è≥ Add Brief Note on Publication Bias
**Location**: "General Equilibrium Considerations" or "Pragmatic Trial Internal Validity" section
**Action**: Add 1-2 sentences: "Publication bias (negative results may not be published) is acknowledged. The dFDA's transparent data infrastructure may partially mitigate this risk, but bias remains a limitation."

#### 28. ‚úÖ Add Brief Note on Comparison Set Rationale - COMPLETED
**Location**: "Comprehensive Comparison Across Intervention Types" section (lines 1045-1067)
**Status**: COMPLETED - Line 1067 includes note: "The comparisons presented focus on dimensions most relevant to decision-makers evaluating treaty adoption. The dFDA compares favorably to both research investments (efficiency per discovery) and direct health interventions (cost per QALY), though comprehensive comparison would require separate frameworks for each dimension."

#### 29. ‚úÖ Acknowledge Inadequate Uncertainty Quantification (Monte Carlo) - COMPLETED
**Location**: "Sensitivity Analysis Approach" section (line 526)
**Status**: COMPLETED - Implemented Monte Carlo simulation (10,000 iterations) with results: Conditional ROI 95% CI [44:1, 66:1], Expected ROI 95% CI [2.7:1, 27:1]. Script: `scripts/monte_carlo_roi_simulation.py`

#### 30. ‚è≥ Verify Variable Name Consistency
**Location**: Technical validation (not in economics.qmd text)
**Action**: Run validation script to verify all variables exist in parameters.py. Check: `dfda_lives_saved_annually`, `dfda_value_per_life_saved`, `traditional_phase3_cost_per_patient` vs `traditional_trial_cost_per_patient`, `dfda_upfront_build` vs `dfda_npv_annual_opex_total`. Fix any inconsistencies.

### Low Priority / Optional

#### 3. ‚è≥ Add Military R&D Spillover Estimate
**Action**: Research estimates of military R&D with civilian applications (20-50%). Add parameter `MILITARY_RD_CIVILIAN_SPILLOVER_PCT`. Add conservative adjustment to peace dividend calculation.

#### 6. ‚è≥ Add Post-Cold War Defense Conversion Data
**Action**: Research post-Cold War military-to-civilian conversion (1989-1995). Find defense worker re-employment rates. Add to references.qmd. Cite in Limitations: "Historical precedent shows 85% re-employed within one year."

#### 7. ‚è≥ Opportunity Cost Table - Contrast with NIH Model
**Action**: Note in opportunity cost discussion: "Traditional research funding (NIH $45B annually) has high cost per QALY at margin due to structural inefficiencies. dFDA targets efficiency (82√ó cost reduction) not just scale."

#### 8. ‚è≥ Add Formal Acknowledgment of Limitations
**Action**: Keep Limitations section concise (~100 lines max). Focus on 5 core limitations with brief description + quantitative sensitivity + why analysis still robust.

---

## Implementation Checklist

### Phase 1: High Priority Text Additions (economics.qmd)
- [x] Todo #15: Enhance opportunity cost analysis section - ‚úÖ COMPLETED (line 946)
- [x] Todo #16: Improve QALY methodology with confidence levels - ‚úÖ COMPLETED (lines 1258, 1262, 1266)
- [x] Todo #17: Enhance external validity discussion - ‚úÖ COMPLETED (lines 1352-1369)
- [x] Todo #18: Add adoption realism discussion - ‚úÖ COMPLETED (lines 571-580)

### Phase 2: Medium Priority Enhancements
- [ ] Todo #26: Add brief note on publication bias
- [x] Todo #28: Add brief note on comparison set rationale - ‚úÖ COMPLETED (lines 1045-1067)
- [x] Todo #29: Acknowledge inadequate uncertainty quantification (Monte Carlo) - ‚úÖ COMPLETED (lines 524-528)
- [ ] Todo #30: Verify variable name consistency

### Phase 3: Low Priority / Optional
- [ ] Todo #3: Add military R&D spillover estimate
- [ ] Todo #6: Add post-Cold War defense conversion data
- [ ] Todo #7: Opportunity cost table - contrast with NIH model
- [ ] Todo #8: Add formal acknowledgment of limitations

### Phase 4: Final Validation
- [ ] Verify all variable references work after running generate-variables-yml.py
- [ ] Check all LaTeX equations render correctly
- [ ] Cross-reference dfda.qmd, dfda-cost-benefit-analysis.qmd, and right-to-trial-fda-upgrade-act.qmd for consistency

---

## Technical Implementation Notes

**For calculations:**
1. Add calculation functions to `dih_models/parameters.py`
2. Create Parameter objects with calculated values, proper metadata (source_ref, confidence, formula, latex)
3. Run `scripts/generate-variables-yml.py` to regenerate `_variables.yml`
4. Reference in economics.qmd using `{{< var parameter_name >}}` syntax
5. Hardcode LaTeX equations in economics.qmd (do not generate dynamically)

**For text-only additions:**
- Add directly to economics.qmd
- Reference existing variables where applicable using `{{< var name >}}`
- Use hardcoded LaTeX for any formulas shown

---

## Completed Items (Reference Only)

**Major completed work:**
- ‚úÖ Expected value analysis (Todo #9) - lines 627-656
- ‚úÖ Automated system clarification (Todo #10) - lines 471-473
- ‚úÖ General equilibrium effects (Todo #11) - lines 1241-1262
- ‚úÖ Peace dividend confidence levels (Todo #12) - lines 445-449
- ‚úÖ Discount rate sensitivity (Todo #13) - lines 528-549 (includes table)
- ‚úÖ RECOVERY trial limitations (Todo #14) - lines 1051-1062
- ‚úÖ Partnership model explanation (Todo #20) - line 754
- ‚úÖ Platform costs distinction (Todo #21) - line 826
- ‚úÖ Cost comparison table (Todo #22) - figure created
- ‚úÖ Observational trial images (Todo #23) - lines 1109-1115
- ‚úÖ QALY confidence levels (Todo #16) - lines 1258, 1262, 1266
- ‚úÖ External validity discussion (Todo #17) - lines 1352-1369
- ‚úÖ Comparison rationale (Todo #28) - lines 1045-1067
- ‚úÖ Time inconsistency discussion (Todo #27) - lines 607-626
- ‚úÖ Counterfactual baseline (Todo #33) - lines 413-429
- ‚úÖ Regulatory and implementation risks (Todo #31) - lines 1393-1477
- ‚úÖ Pre-1962 context and thalidomide (Todo #0a) - lines 542-554

For detailed historical record of all completed work, see git history.
